Get in touch
Our Client Services team is on hand to help. Please call us at 866.776.5907, Option 3.
Rapid AML Therapeutic Panel
- Molecular
The Rapid AML Therapeutic Panel analyzes 13 biomarkers through a combination of bi-directional Sanger sequencing, PCR, and FISH as listed below.
Sanger sequencing (1 gene): TP53
PCR/Fragment Analysis (5 genes): FLT3 (ITD and TKD), IDH1/IDH2, NPM1, and CEBPA
FISH probes: 5q-, -5 (5p15, 5q31, 5q33) | 7q-, -7 (Cen 7, 7q22, 7q31) | RUNX1/RUNX1T1 (ETO/AML1) t(8;21) | MLL (11q23) | PML/RARA t(15;17) | CBFB inv(16), t(16;16) | 17p- (TP53 17p13.1, NF1 17q11.2)
Test reports include a summary of all results together.
Turnaround time
4-5 Days for FLT3, IDH1/IDH2, and FISH. 7-10 Days for NPM1, CEBPA, and TP53.
Level of Service
- Global
New York Approved: No
Storage and Transportation
Please select extract & hold - DNA if specimen hold service is desired. Use cold pack for transport, making sure cold pack is not in direct contact with specimen.
CPT Code(s)*
Molecular: Client-bill only, if ordered concurrently with Neo Comprehensive™ – Myeloid Disorders, or one of the NeoTYPE® Heme Profiles, such as Myeloid Disorders Profile, AML Prognostic Profile, or MDS/CMML Profile. See Notes if ordered alone.
*The CPT codes provided with our test descriptions are based on AMA guidelines and are for informational purposes only. Correct CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payor being billed.
Last Updated: January 22, 2025